Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 145.89 Billion KRW | 23.92% |
| 2022 | 117.73 Billion KRW | -0.08% |
| 2021 | 117.83 Billion KRW | 6.62% |
| 2020 | 110.51 Billion KRW | -8.45% |
| 2019 | 120.71 Billion KRW | -15.45% |
| 2018 | 142.77 Billion KRW | 5.0% |
| 2017 | 135.98 Billion KRW | 5.13% |
| 2016 | 129.34 Billion KRW | 7.93% |
| 2015 | 119.83 Billion KRW | 7.01% |
| 2014 | 111.99 Billion KRW | -4.25% |
| 2013 | 116.96 Billion KRW | 8.12% |
| 2012 | 108.18 Billion KRW | -10.92% |
| 2011 | 121.44 Billion KRW | 0.75% |
| 2010 | 120.53 Billion KRW | 25.4% |
| 2009 | 96.11 Billion KRW | 4.78% |
| 2008 | 91.73 Billion KRW | 6.32% |
| 2007 | 86.28 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 36.22 Billion KRW | -5.97% |
| 2024 Q2 | 33.95 Billion KRW | -6.29% |
| 2023 Q4 | 38.52 Billion KRW | 31.06% |
| 2023 FY | 145.89 Billion KRW | 23.92% |
| 2023 Q1 | 28.03 Billion KRW | -27.55% |
| 2023 Q2 | 27.43 Billion KRW | -2.13% |
| 2023 Q3 | 29.39 Billion KRW | 7.14% |
| 2022 FY | 117.73 Billion KRW | -0.08% |
| 2022 Q3 | 31.6 Billion KRW | 9.08% |
| 2022 Q4 | 38.69 Billion KRW | 22.43% |
| 2022 Q1 | 25.96 Billion KRW | 37.28% |
| 2022 Q2 | 28.97 Billion KRW | 11.59% |
| 2021 Q2 | 30.77 Billion KRW | 18.41% |
| 2021 Q4 | 18.91 Billion KRW | -55.12% |
| 2021 Q3 | 42.14 Billion KRW | 36.93% |
| 2021 FY | 117.83 Billion KRW | 6.62% |
| 2021 Q1 | 25.99 Billion KRW | -2.44% |
| 2020 FY | 110.51 Billion KRW | -8.45% |
| 2020 Q1 | 27.42 Billion KRW | 9.17% |
| 2020 Q3 | 27.54 Billion KRW | -4.73% |
| 2020 Q4 | 26.64 Billion KRW | -3.26% |
| 2020 Q2 | 28.9 Billion KRW | 5.42% |
| 2019 Q1 | 31.76 Billion KRW | -9.31% |
| 2019 Q2 | 33.03 Billion KRW | 4.01% |
| 2019 Q4 | 25.11 Billion KRW | -18.44% |
| 2019 FY | 120.71 Billion KRW | -15.45% |
| 2019 Q3 | 30.79 Billion KRW | -6.77% |
| 2018 Q4 | 35.02 Billion KRW | -0.91% |
| 2018 FY | 142.77 Billion KRW | 5.0% |
| 2018 Q3 | 35.34 Billion KRW | -4.79% |
| 2018 Q2 | 37.12 Billion KRW | 5.22% |
| 2018 Q1 | 35.28 Billion KRW | 8.56% |
| 2017 Q1 | 32.78 Billion KRW | 0.05% |
| 2017 Q2 | 34.7 Billion KRW | 5.87% |
| 2017 Q3 | 35.99 Billion KRW | 3.71% |
| 2017 FY | 135.98 Billion KRW | 5.13% |
| 2017 Q4 | 32.5 Billion KRW | -9.7% |
| 2016 Q4 | 32.76 Billion KRW | 0.93% |
| 2016 Q1 | 31.73 Billion KRW | 5.43% |
| 2016 FY | 129.34 Billion KRW | 7.93% |
| 2016 Q2 | 32.39 Billion KRW | 2.08% |
| 2016 Q3 | 32.46 Billion KRW | 0.22% |
| 2015 Q4 | 30.09 Billion KRW | -3.28% |
| 2015 Q2 | 29.65 Billion KRW | 2.36% |
| 2015 FY | 119.83 Billion KRW | 7.01% |
| 2015 Q3 | 31.11 Billion KRW | 4.94% |
| 2015 Q1 | 28.96 Billion KRW | 12.0% |
| 2014 Q2 | 27.14 Billion KRW | -10.41% |
| 2014 Q1 | 30.3 Billion KRW | 2.72% |
| 2014 FY | 111.99 Billion KRW | -4.25% |
| 2014 Q4 | 25.86 Billion KRW | -9.8% |
| 2014 Q3 | 28.67 Billion KRW | 5.63% |
| 2013 Q3 | 30.56 Billion KRW | 8.01% |
| 2013 FY | 116.96 Billion KRW | 8.12% |
| 2013 Q2 | 28.29 Billion KRW | -1.1% |
| 2013 Q1 | 28.6 Billion KRW | 5.29% |
| 2013 Q4 | 29.5 Billion KRW | -3.47% |
| 2012 Q1 | 26.49 Billion KRW | -7.49% |
| 2012 Q2 | 24.94 Billion KRW | -5.83% |
| 2012 Q3 | 29.57 Billion KRW | 18.56% |
| 2012 Q4 | 27.17 Billion KRW | -8.12% |
| 2012 FY | 108.18 Billion KRW | -10.92% |
| 2011 Q4 | 28.63 Billion KRW | -8.05% |
| 2011 Q1 | 30.04 Billion KRW | -10.52% |
| 2011 Q2 | 31.61 Billion KRW | 5.21% |
| 2011 FY | 121.44 Billion KRW | 0.75% |
| 2011 Q3 | 31.14 Billion KRW | -1.48% |
| 2010 FY | 120.53 Billion KRW | 25.4% |
| 2010 Q2 | 29.84 Billion KRW | 9.58% |
| 2010 Q3 | 29.87 Billion KRW | 0.11% |
| 2010 Q1 | 27.23 Billion KRW | 11.75% |
| 2010 Q4 | 33.58 Billion KRW | 12.4% |
| 2009 Q3 | 23.58 Billion KRW | -2.47% |
| 2009 Q4 | 24.37 Billion KRW | 3.34% |
| 2009 Q1 | 23.98 Billion KRW | 8.91% |
| 2009 FY | 96.11 Billion KRW | 4.78% |
| 2009 Q2 | 24.18 Billion KRW | 0.82% |
| 2008 Q3 | 23.64 Billion KRW | 4.36% |
| 2008 Q4 | 22.02 Billion KRW | -6.87% |
| 2008 FY | 91.73 Billion KRW | 6.32% |
| 2008 Q1 | 23.41 Billion KRW | -0.72% |
| 2008 Q2 | 22.65 Billion KRW | -3.23% |
| 2007 Q1 | 19.23 Billion KRW | 0.0% |
| 2007 Q3 | 22.67 Billion KRW | 9.05% |
| 2007 Q2 | 20.78 Billion KRW | 8.06% |
| 2007 FY | 86.28 Billion KRW | 0.0% |
| 2007 Q4 | 23.58 Billion KRW | 4.03% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -213.711% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 59.932% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 26.646% |
| HANDOK Inc. | 151.36 Billion KRW | 3.617% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -117.021% |
| Yuhan Corporation | 564.5 Billion KRW | 74.156% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 54.722% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -514.356% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 82.546% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -94.419% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 26.674% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -258.9% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -54.357% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -3.575% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -213.711% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -320.245% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -89.917% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1311.159% |
| JW Holdings Corporation | 446.15 Billion KRW | 67.3% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 29.704% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 77.738% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 56.538% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -85.566% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -93.907% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -102.033% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 20.631% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -213.711% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 50.565% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 78.594% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 56.538% |
| Yuhan Corporation | 564.5 Billion KRW | 74.156% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 27.713% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -105.657% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -47.325% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 56.538% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 15.907% |
| CKD Bio Corp. | 5.01 Billion KRW | -2811.83% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 42.615% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 20.765% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -48.679% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -85.566% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 60.729% |
| Boryung Corporation | 333.26 Billion KRW | 56.224% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -191.518% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 26.674% |
| JW Lifescience Corporation | 51.32 Billion KRW | -184.25% |